OXIDATION OF 17 ALPHA-ETHYNYLESTRADIOL BY HUMAN-LIVER CYTOCHROME-P-450
- 1 May 1988
- journal article
- research article
- Vol. 33 (5) , 500-508
Abstract
One of the classic examples of adverse drug interactions involves pregnancies in women using the oral contraceptive 17.alpha.-ethynylestradiol who also ingest rifampicin or barbiturates or hydantoins. Previous work had demonstrated increased metabolism (2-hydroxylation) of 17.alpha.-ethynylestradiol in individuals using rifampicin. In this report evidence is presented for the involvement of a specific form of human cytochrome P-450, termed P-450NF, in this phenomenon. Although purified P-450NF has only relatively low catalytic 17.alpha.-ethynylestradiol 2-hydroxylase activity, antibodies raised to P-450NF specifically inhibited > 90% of the activity in liver microsomes which had either high or low catalytic activity. When different liver samples were compared, rates of microsomal 17.alpha.-ethynylestradiol 2-hyroxylation were highly correlated with amounts of immunochemically measured P-450NF or rates of nifedipine oxidation, a characteristic activity of P-450NF. Prior incubation of human liver microsomes with NADPH and troleandomycin resulted in decreased 17.alpha.-ethynylestradiol 2-hydroxylation. In addition, 17.alpha.-ethynylestradiol appears to be a mechanism-based inhibitor in human liver microsomes, as shown by the loss of both spectrally detectable cytochrome P-450 and 17.alpha.-ethynylestradiol 2-hydroxylase activity during incubation in the presence of NADPH. Additional experiments did not show any evidence for the involvement of a number of other human cytochrome P-450 enzymes in 17.alpha.-ethynylestradiol 2-hydroxylation (i.e., P-450DB, P-450PA, P-450MP, P-450j). These results are consistent with the view that P-450NF is the major enzyme involved in 17.alpha.-ethynylestradiol oxidation and that drugs and hormones which influence the expression and activity of this enzyme can influence the efficacy and side effects of this compound.This publication has 25 references indexed in Scilit:
- Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.Journal of Biological Chemistry, 1985
- Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.Proceedings of the National Academy of Sciences, 1984
- CHANGES IN ESTROGEN METABOLISM AFTER CHRONIC ORAL-CONTRACEPTIVE ADMINISTRATION IN THE RHESUS-MONKEY1984
- Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresisBiochemistry, 1982
- The biotransformation of 17α-ethynyl[3H]estradiol in the rat: Irreversible binding and biliary metabolitesXenobiotica, 1982
- Metabolic activation of acetylenic substituents to derivatives in the rat causing the loss of hepatic cytochrome P-450 and haemBiochemical Journal, 1978
- Decreased liver cytochrome P-450 in rats caused by norethindrone or ethynyloestradiolBiochemical Journal, 1977
- Nitrosoalkanes as Fe(II) Ligands in the 455-nm-Absorbing Cytochrome P-450 Complexes Formed from Nitroalkanes in Reducing ConditionsEuropean Journal of Biochemistry, 1977
- Cytochrome P-450-mediated oxidation of 2-hydroxyestrogens to reactive intermediatesBiochemical and Biophysical Research Communications, 1976
- The Carbon Monoxide-binding Pigment of Liver MicrosomesJournal of Biological Chemistry, 1964